Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results
March 24, 2022 08:00 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the...
Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline
January 10, 2022 08:00 ET
|
Surrozen, Inc.
-Initiation of Phase 1 clinical trials of SZN-1326 and SZN-043 expected in third quarter 2022 -Acceleration of preclinical programs includes nomination of lead candidate SZN-413 for retinopathies and...
Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
January 05, 2022 08:00 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the...
Surrozen Reports Third Quarter 2021 Financial Results
November 15, 2021 16:00 ET
|
Surrozen, Inc.
Product Candidates SZN-1326 and SZN-043 Advance Toward Initiation of Clinical Studies in 2022 Expanding and Advancing Discovery Stage Pipeline in Multiple Disease Settings SOUTH SAN FRANCISCO,...
Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases
November 15, 2021 08:00 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair...
Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference
November 15, 2021 08:00 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc., (NASDAQ: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt...
Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference
November 05, 2021 08:00 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc., (Nasdaq: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt...
Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week
October 05, 2021 16:30 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair...
Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources
September 23, 2021 08:30 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc. (Nasdaq: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt...
Surrozen Debuts as Publicly Traded Leader in Wnt Biology and Tissue Regeneration
August 11, 2021 17:30 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen”), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and...